The manufacturers of AstraZeneca, one of the vaccines used during the rise of the COVID-19 pandemic, have announced that it has started a global withdrawal of its vaccines.
The pharmaceutical giant acknowledged the existence of an uncommon adverse effect known as Thrombosis with Thrombocytopenia Syndrome (TTS).
This condition, characterized by the formation of blood clots that obstruct veins or arteries, can manifest through symptoms such as unilateral leg pain and swelling, chest discomfort, or one-sided body numbness.
In an update on the European Medicines Agency’s website Wednesday, the regulator said that the approval for AstraZeneca’s Vaxzevria had been withdrawn “at the request of the marketing authorization holder.”
The vaccine, initially approved in January 2021, faced safety concerns over rare blood clots, prompting various countries to halt its use temporarily.
While the EU regulator determined that the overall risk was low, doubts lingered. Additionally, limited data on its effectiveness in older adults led to initial restrictions.
Billions of doses of the AstraZeneca vaccine were distributed to poorer countries through a U.N.-coordinated program, as it was cheaper and easier to produce and distribute. However? studies later suggested that the pricier messenger RNA vaccines made by Pfizer-BioNTech and Moderna provided better protection against COVID-19 and its many variants, and most countries switched to those shots.
The U.K.’s national coronavirus immunization program in 2021 heavily relied on AstraZeneca’s vaccine, which was largely developed by scientists at Oxford University with significant financial government support.
But even Britain later resorted to buying the mRNA vaccines for its COVID booster vaccination programs and the AstraZeneca vaccine is now rarely used globally.